USCAP 2024: Utilization of Artificial Intelligence for the identification of microinvasive carcinoma of the breast

Back

This study, conducted at Brigham and Women’s Hospital and Champalimaud Foundation, evaluated Galen Breast’s performance in identifying microinvasive carcinoma of the breast (MI). The results indicate that Galen Breast’s AI algorithm is highly accurate in detecting MI and has the potential to enhance accuracy and consistency in the diagnosis of MI, reduce pathologist time spent trying to identify foci of MI, and possibly reduce the need for immunohistochemical staining to confirm the presence of MI foci.

Back

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our AI platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.

By providing my details I agree to the IBEX-AI Terms and conditions and Privacy policy. I also agree to receive emails form IBEX-AI and I understand that I may opt out of IBEX-AI subscriptions at any time.

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our AI platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.

By providing my details I agree to the IBEX-AI Terms and conditions and Privacy policy. I also agree to receive emails form IBEX-AI and I understand that I may opt out of IBEX-AI subscriptions at any time.
Articles

How is artificial intelligence rising to the challenge in breast cancer diagnosis?

Articles

How ‘game-changing’ AI is helping discover cancer for the first time in UK | ITV News

Videos

The AI revolution in cancer diagnostics with Joseph Mossel, CEO of Ibex Medical Analytics